Life Sciences Private Capital will invest in early and growth stage healthcare companies.

J.P. Morgan Asset Management today announced the launch of a new life sciences private equity team, Life Sciences Private Capital, as part of its J.P. Morgan Private Capital arm, a growth equity and private credit investment platform.

The new Life Sciences team will invest in both early and growth stage healthcare companies across multiple strategies aligned to specific market opportunities, with a focus on novel therapeutics and technologies in several target areas including Genetic Medicine, Oncology, Neurodegenerative Disease, Rare Diseases, Autoimmunity, AI/ML platforms, Metabolic Diseases and Neuropsychology. (CISION PR Newswire)

J.P. Morgan: Life Sciences Private Capital

Industry expert Dr. Stephen Squinto has been appointed as Chief Investment Officer and Managing Partner of Life Sciences Private Capital.

Dr. Squinto joins from OrbiMed Advisors and brings more than 30 years of experience in the biotechnology company building and investing space, having co-founded and built numerous biotechnology companies including Alexion Pharmaceuticals and acting as a key scientific founder of Regeneron Pharmaceuticals.

“As advances in genomics, biomarkers and data science converge, we are seeing firsthand the transformative impact that biomedical innovation can offer to patients at all stages of life and we expect much more to come in the next decade,” said Dr Squinto. “J.P. Morgan’s existing presence in the healthcare sector will give us a significant sourcing advantage as we seek to identify innovative and transformative therapeutics companies.”

“Our new Life Sciences Private Capital team combines some of the industry’s most revered biotech investors, operators and founders with J.P. Morgan’s extensive healthcare ecosystem to capture compelling investment opportunities in the biotech sector, which is on the cusp of a golden age of therapeutic innovation,” said Brian Carlin, Chief Executive Officer, J.P. Morgan Private Capital.

Related Story: AI-Powered, Precision Medicine Startup Tempus Raises $275M In Equity And Debt

Photo by Lucas Vasques on Unsplash